PRELUDE THERAPEUTICS INC
Income Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Sep 2024 |
|---|---|---|---|---|---|---|---|
| Revenue | $5.7M | $4.6M | $5.6M | $6.5M | $0 | $0 | $3.0M |
| Cost of Revenue | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — |
| Operating Expenses | |||||||
| Research & Development | $16.1M | $13.6M | $18.0M | $21.7M | $25.8M | $28.8M | $29.5M |
| SG&A Expense | $5.0M | $5.2M | $5.0M | $5.2M | $6.4M | $5.8M | $7.9M |
| Operating Income | $-15.5M | $-14.2M | $-17.3M | $-20.4M | $-32.2M | $-34.6M | $-34.4M |
| Operating Margin | -270.9% | -309.5% | -307.6% | -314.1% | — | — | -1,145.9% |
| Interest Expense | — | — | — | — | — | — | — |
| Pretax Income | — | — | — | — | — | — | — |
| Income Tax Expense | — | — | — | — | — | — | — |
| Net Income | $-13.9M | $-10.4M | $-16.5M | $-19.7M | $-31.2M | $-32.1M | $-32.3M |
| Net Margin | -244.1% | -226.7% | -291.8% | -303.5% | — | — | -1,075.7% |
| EPS (Basic) | $-0.14 | $-0.13 | $-0.20 | $-0.26 | $-0.41 | $-0.42 | $-0.43 |
| EPS (Diluted) | $-0.14 | $-0.13 | $-0.20 | $-0.26 | $-0.41 | $-0.42 | $-0.43 |
| Shares Outstanding (Basic) | 98.4M | 82.5M | 77.0M | 76.1M | 76.0M | 76.0M | 75.9M |
| Shares Outstanding (Diluted) | 98.4M | 82.5M | 77.0M | 76.1M | 76.0M | 76.0M | 75.9M |
| Dividends Per Share | — | — | — | — | — | — | — |